Information Library

Results for: Presentations - Market Access

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Leveraging social networks to conduct observational research

    March 26, 2011
    Quintiles’ presentation describes the benefits of social networks in terms of patient identification, cost and time, relative to traditional observational research approaches.

  • The Use of Large Simple Trials

    February 25, 2011
    Quintiles presentation at CBI Late Phase Conference explores the design and application of Large Simple Trials as a cost effective approach to delivering high quality observational research data.

  • The Art and Science of Segmentation

    October 9, 2010
    Quintiles presentation delivers fresh insights into the art and science of segmentation and its practical applications in market research. The presentation features a key Pfizer case study.

  • Executive Vision Forum 2010: Convergence of Stakeholders

    July 9, 2010
    A Holistic Approach to Patient Outcomes - Brian Sweet, CPO, WellPoint. Presentation about the convergence of stakeholders.

  • Executive Vision Forum 2010: Clinical and Commercial Convergence

    July 8, 2010
    Pasquale Cetera, VP Portfolio Management, Merck, presentation about the convergence of Clinical and Commercial.

  • Award Winning Poster at ISPOR EU

    November 17, 2009
    Pascale Peeters' award winning poster presented at ISPOR EU 2009 in Paris.

  • Orphan Drugs in the U.S.

    June 24, 2009
    Presentation by Dr. John Doyle, Market Access Practice Leader, from ISPOR 14th Annual International Meeting 2009(International Society for Pharmacoeconomics and Outcomes Research) on “Orphan Drugs' Market Access in the U.S.”

  • Effects of NICE HTA on Drug Prescribing and Expenditures in the U.S.

    June 24, 2009
    Presentation by Dr. John Doyle, Market Access Practice Leader, from ISPOR 14th Annual International Meeting 2009 (International Society for Pharmacoeconomics and Outcomes Research) on “The Effects of NICE HTA on Drug Prescribing and Expenditures in the U.S.”

  • Poised for success

    June 16, 2009
    Learn how a holistic life cycle approach can improve your commercial organization's productivity and flexibility

Page 1 of 1 (9 results)

Subscribe to Email Based on Your Interests

Set preferences